This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KRBP Kiromic BioPharma (KRBP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisEarningsFDA EventsHeadlinesShort InterestTrendsBuy This Stock About Kiromic BioPharma Stock (NASDAQ:KRBP) 30 days 90 days 365 days Advanced Chart Get Kiromic BioPharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.21▼$1.6652-Week Range N/AVolume107,749 shsAverage Volume11,347 shsMarket Capitalization$330 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. Read More Receive KRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiromic BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address KRBP Stock News HeadlinesKRBPQ Kiromic BioPharma, Inc.May 30, 2025 | seekingalpha.comHouston-based Kiromic BioPharma finds buyer for assets after filing Chapter 7April 7, 2025 | bizjournals.comTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative... | InvestorPlace (Ad)Houston cancer treatment co. files for bankruptcy months after settling SEC chargesMarch 21, 2025 | bizjournals.comKiromic BioPharma Files for Chapter 7 BankruptcyMarch 21, 2025 | marketwatch.comKiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free SurvivalFebruary 18, 2025 | finance.yahoo.comKiromic says Deltacel-01 trial patient reaches progression-free survivalFebruary 18, 2025 | markets.businessinsider.comKiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01January 21, 2025 | uk.finance.yahoo.comSee More Headlines KRBP Stock Analysis - Frequently Asked Questions How were Kiromic BioPharma's earnings last quarter? Kiromic BioPharma, Inc. (NASDAQ:KRBP) released its quarterly earnings results on Friday, November, 8th. The company reported ($0.65) earnings per share for the quarter. When did Kiromic BioPharma's stock split? Shares of Kiromic BioPharma reverse split on Monday, March 13th 2023.The 1-30 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Kiromic BioPharma IPO? Kiromic BioPharma (KRBP) raised $16 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 1,200,000 shares at a price of $12.00-$14.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO and Paulson Investment Company was co-manager. What other stocks do shareholders of Kiromic BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kiromic BioPharma investors own include Athenex (ATNX), KLX Energy Services (KLXE), Brainstorm Cell Therapeutics (BCLI), NGL Energy Partners (NGL), Orchard Therapeutics (ORTX), TherapeuticsMD (TXMD) and Achilles Therapeutics (ACHL). Company Calendar Last Earnings11/08/2024Today8/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRBP CIK1792581 Webwww.kiromic.com Phone832-968-4888FaxN/AEmployees60Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.90 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-277.46% Debt Debt-to-Equity RatioN/A Current Ratio0.16 Quick Ratio0.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($8.29) per share Price / BookN/AMiscellaneous Outstanding Shares1,571,000Free Float1,217,000Market Cap$330 thousand OptionableNot Optionable Beta1.66 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:KRBP) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiromic BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiromic BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.